This technology has the possibility to effectively treat children and adults with metastatic osteosarcoma (bone cancer) where the disease has progressed beyond the first and second line treatment stage. Inven2 is seeking to out-license the technology to pharmaceutical companies and/or biotechnology SMEs for clinical trials either as a single intervention or combination treatment with existing first, second, or third line interventions. Solid tumours are a cause of significant morbidity and mortality. The field of immunotherapy represents a market of 100 billion US dollars and is growing steadily.
CAR T cell therapy (autologous) that recognizes metastatic and local osteosarcoma tumour cells.
Our data demonstrates an effective and highly significant reduction in tumour mass once the drug is injected by systemic i.p. administration. We have shown this in a preclinical model of Osteosarcoma.
Not yet published as a scientific article.
Norway priority patent application filed in 2018, continuation filed at PCT. Published in June 2019. An additional three patent applications were filed in 2019.